Atea Pharmaceuticals Inc (AVIR) - Total Liabilities
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has total liabilities worth $39.78 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Atea Pharmaceuticals Inc equity growth rate to track the company's year-over-year net asset growth rate.
Atea Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Atea Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rejlers AB (publ)
ST:REJL-B
|
Sweden | Skr2.12 Billion |
|
Saratoga Investment Corp
NYSE:SAR
|
USA | $783.76 Million |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
Greece | €494.17 Million |
|
Meteoric Resources NL
F:RNF
|
Germany | €8.58 Million |
|
Comp SA
WAR:CMP
|
Poland | zł313.92 Million |
|
Select Harvests Ltd
AU:SHV
|
Australia | AU$414.55 Million |
|
Changchun Yidong Clutch Co Ltd
SHG:600148
|
China | CN¥639.85 Million |
|
Huitong Construction Group Co.Ltd.
SHG:603176
|
China | CN¥4.71 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Atea Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Atea Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atea Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Atea Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $39.78 Million | +54.20% |
| 2024-12-31 | $25.80 Million | -35.13% |
| 2023-12-31 | $39.78 Million | +52.19% |
| 2022-12-31 | $26.14 Million | -58.39% |
| 2021-12-31 | $62.81 Million | -80.11% |
| 2020-12-31 | $315.83 Million | +340.83% |
| 2019-12-31 | $71.64 Million | +0.88% |
| 2018-12-31 | $71.02 Million | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more